SIShahin Isha

Shahin Isha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shahin Isha has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association Between Veno-Venous Extracorporeal Membrane Oxygenation and Right Ventricular Dysfunction in Acute Respiratory Distress Syndrome Patients: A Multicenter Retrospective Propensity-Matched Study

    by Shahin Isha, Aditya A. Khanijo, Govind Pandompatam, John Kyle Bohman, Troy G. Seelhammer, Ayan Sen, John Haney, Ricardo Diaz Milian, Devang K. Sanghavi, Pablo Moreno Franco, et al.

    Emerging evidence links veno-venous extracorporeal membrane oxygenation (VV-ECMO) to right ventricular (RV) dysfunction, but the relative contribution of ECMO versus underlying disease progression remains unclear. We conducted a multicenter, retrospective, propensity-matched study including 408 intubated acute respiratory distress syndrome (ARDS) patients who were admitted between January 2020 and October 2024 in a quaternary referral hospital network within the United States and underwent at least two transthoracic echocardiograms (TTEs) after intubation. Using 1:2 propensity score matching, we adjusted for baseline comorbidities, baseline hemoglobin, lactate, and worst PaO 2 /FiO 2 ratio (P/F). Longitudinal echocardiographic changes were analyzed with a cumulative link mixed model (CLMM), evaluating RV size and function as ordinal outcomes. Within 408 patients (112 received ECMO support), propensity matching identified 55 ECMO and 110 non-ECMO patients with balanced baseline characteristics. Among 469 serial echocardiograms, RV size and function worsened more frequently in ECMO patients. In longitudinal modeling, ECMO use alone was not associated with RV dilation ( p = 0.23) or dysfunction ( p = 0.43). However, longer ECMO duration was associated with RV dilation (OR: 1.04 per day, p = 0.004) and dysfunction (odds ratio [OR]: 1.04 per day, p < 0.001). Higher ECMO circuit flow had a trend toward progressive RV dilation and dysfunction but did not reach statistical significance. These findings highlight the need for vigilant RV monitoring during ECMO support.

  • A Silent Complication: Review of Lingual Edema Following Intubation

    by Surabhi Maheshwari, Yash Vardhan Trivedi, Shahin Isha, Abdulmoiz Abdulwali, William P Saliski

    Objective: To synthesize published clinical evidence on post-intubation lingual edema, focusing on pathophysiology, clinical presentation, diagnosis, management, and prevention strategies. Methods: A narrative review was performed using PubMed, Scopus, and EMBASE from inception through April 2025. Search terms included “tongue edema,” “macroglossia,” “lingual edema,” “endotracheal intubation,” “airway management,” and “critical care.” Eligible English-language reports describing lingual edema in adults following endotracheal intubation were included and synthesized qualitatively. Results: A total of 48 studies were included, consisting predominantly of case reports, case series, and observational studies. Conclusions: Post-intubation lingual edema is an uncommon but potentially life-threatening complication. Early recognition, mechanism-directed management, and preventive strategies, including atraumatic airway techniques, optimal positioning, frequent reassessment and device repositioning, and selective consideration of bradykinin-targeted therapy when angioedema is suspected, are critical to reducing morbidity.

  • Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes

    by Vrutti Patel, Saurabh Sujanyal, Lekhya Raavi, Sophia G. Blumenfeld, Faiz Saleem, Said Bateh, Abby Hanson, Anek Jena, Shahin Isha, Katie L. Kunze, et al.

    Background: Ketamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU patients. Methods: We conducted a retrospective study of adults admitted to the ICU who received IV ketamine (0.3-0.75 mg/kg over 40 min on three consecutive days) for depressive symptoms. Changes in depressive symptoms were assessed using routine clinical documentation by physicians, nurses, and occupational and physical therapists. Hemodynamic parameters (blood pressure and heart rate) were recorded before and up to 120 min after infusion. The primary outcome was to evaluate depressive symptoms while the secondary outcome was to assess hemodynamic changes post transfusion. Results: Thirty-four patients met criteria, including 18 solid organ transplant recipients. Median age was 59 years; 61.8% were male. Ketamine was associated with improvement in apparent sadness (90.0% vs 52.2%, P < .05) and reported sadness (95.0% vs 59.1%, P < .05). In transplant recipients, improvement in apparent sadness remained significant (80.0% vs 41.7%, P < .05). Hemodynamic parameters remained stable; heart rate increased transiently at 15-30 min post-infusion, returning to baseline by 60-90 min. Adverse effects observed were anxiety (12.5%), restlessness and/or agitation (10.4%), and dissociation (8.16%). Conclusion: Subanesthetic ketamine improved specific depressive symptoms in critically ill ICU patients without significant hemodynamic instability. These findings support its potential as a rapid-acting antidepressant in the ICU, warranting further prospective trials.

  • Association of Pulmonary Artery Catheter Utilization with Outcomes in Patients with Cardiogenic Shock: A Retrospective Propensity-Matched Study

    by Shahin Isha, Akshat Banga, Ananya Biswas, Bekure Siraw, Tamal Basak, Mubashir Ayaz Ahmed, Juveriya Yasmeen, Titilope Olanipekun, Anirban Bhattacharyya, Devang K. Sanghavi, et al.

    Purpose: Despite the need for advanced hemodynamic monitoring, the role of the pulmonary artery catheter (PAC) in cardiogenic shock (CS) remains controversial due to conflicting evidence from previous studies. Material and Methods: This single-center retrospective study utilized the MIMIC-IV database to assess the impact of PAC use on 30-day in-hospital mortality and clinical outcomes in CS patients admitted between 2008 and 2019. Propensity score matching (PS) and inverse propensity treatment weighting (IPTW) were employed to adjust for baseline differences. The primary outcome was 30-day in-hospital mortality; secondary outcomes included hospital and ICU length of stay and complications. Cox proportional hazard ratio analyses were performed to evaluate the association between PAC use and mortality outcomes. Results: The final cohort consisted of 1940 adult CS patients, with 134 receiving PAC and 1806 not. PAC use significantly reduced 30-day in-hospital mortality (PS-matched HR 0.57, 95% CI: 0.39-0.83; IPTW HR 0.58, 95% CI: 0.35-0.96) but was associated with longer hospital stays (16.47 vs 12.37 days) and ICU stays (9.26 vs 7.52 days). Conclusion: PAC use in CS patients was associated with improved short-term survival but also with longer hospitalization and potential complications, underscoring the need for careful patient selection and further research.

  • Hospital Safety-Net Burden and Outcomes of COVID-19 Hospitalizations in the US: Analysis of a National Multicenter Database

    by Titilope Olanipekun, Joseph Heaton, Temidayo Abe, Abimbola Chris-Olaiya, Bekure B. Siraw, Isha Shahin, Ndausung Udongwo, Iván A Huespe, Devang Sanghavi

    Background: Safety-net hospitals (SNH) provide care to a significant proportion of low-income, uninsured, and underserved populations disproportionately affected by the COVID-19 pandemic. We evaluated the impact of safety-net burden on outcomes of COVID-19 hospitalizations. Methods: We identified patients aged ≥ 18 years hospitalized with COVID-19 from the nationwide inpatient database using the International Classification of Diseases, Tenth Edition (ICD-10-CM) code U07.1. The primary study outcomes were inpatient mortality, respiratory failure requiring mechanical ventilation, and tracheostomy use. Secondary outcomes were total hospitalization costs (THC) and length of hospital stay (LOS). Multivariable logistic regression was used to compare the primary and secondary outcomes in HBH and medium safety-net burden (MBH) with lower-burden hospitals (LBH) (reference). Results: An estimated 2,608,232 COVID-19 hospitalizations met the inclusion criteria, with 68.7% occurring in HBH, 22.8% in MBH, and 8.5% in LBH. On adjusted multivariable analysis, HBH was associated with increased odds of inpatient mortality (aOR 1.19, 95% CI 1.09-1.28) compared with LBH. Both HBH (aOR 1.30, 95% CI 1.21-1.40) and MBH (aOR 1.14, 95% CI 1.06-1.24) demonstrated increased odds of mechanical ventilation compared with LBH. THC was lower in HBH and MBH compared with LBH. The LOS was similar across safety net burden categories. Conclusion: After adjusting for patient- and hospital-level factors, COVID-19 hospitalizations at HBH had inferior inpatient outcomes compared with LBH. Targeted policy reforms are needed to address the underlying causes of these disparities and increase our health systems’ readiness for future crises, particularly in underserved communities.

  • Open Access

    Twist of Fate: Life-Threatening SMA Thrombosis Caused by Mesenteric Torsion Post-Roux-en-Y Weight Loss

    by Mohamed Ayman Ebrahim, Shahin Isha, Andranik Bedross, Parth Patel, Ashok Kumar

    Superior mesenteric artery (SMA) thrombosis is rare yet critical illness that can result in lethal bowel ischemia and infarction. This report details a case of SMA thrombosis with associated superior mesenteric vein (SMV) narrowing, secondary to mesenteric torsion in a 26-year-old female with history of Roux-en-Y gastric bypass surgery. The patient’s presenting symptoms were severe epigastric pain, vomiting, and significant anemia. Imaging confirmed SMA thrombosis with early signs of bowel ischemia. Interventional radiology promptly performed an SMA angiogram and initiated thrombolysis with a tenecteplase infusion, which led to near-complete resolution of the thrombus. This case draws attention to the necessity for early diagnosis and swift management of SMA thrombosis, particularly in post-surgical patients with altered gastrointestinal anatomy. The resolution of this case demonstrates the value of a collaborative care, combining interventional radiology and general surgery to prevent bowel ischemia.

  • Association of estimated plasma volume with new onset acute kidney injury in hospitalized COVID-19 patients

    by Shahin Isha, Prasanth Balasubramanian, Lekhya Raavi, Abby J. Hanson, Anna Jenkins, Parthkumar Satashia, Arvind Balavenkataraman, Iván A. Huespe, Aysun Tekin, Vikas Bansal, et al.


  • Assessing Right Ventricle Over Time in Patients on Veno-Venous Extracorporeal Membrane Oxygenation: Insights From Serial Echocardiography

    by Shahin Isha, Sai Abhishek Narra, Humera Batool, Sadhana Jonna, Abhishek Giri, Olivia Herrmann, Amari Dyson, Mick D. Nichols, Rachel Hannon, Si Pham, et al.

    Extracorporeal membrane oxygenation (ECMO) is often used in acute respiratory distress syndrome (ARDS) with refractory hypoxemia. There is limited literature highlighting the development of right ventricular (RV) failure while on ECMO. We conducted a retrospective multicenter observational study including 70 patients who were placed on veno-venous (VV)-ECMO for respiratory failure at Mayo Clinic, Jacksonville, and Mayo Clinic, Rochester, between January 2018 and June 2022 and had at least two post-ECMO transthoracic echoes. The primary outcomes were the incidence and progression of RV dysfunction and dilatation. The secondary outcome was in-patient mortality. Among 70 patients in our cohort, 60.6% had a normal RV function at the time of ECMO placement, whereas only 42% had a normal RV function at the second post-ECMO echo. On multinomial regression, a moderate decrease in RV function was associated with ECMO flow (odds ratio [OR] = 2.32, p = 0.001) and ECMO duration (OR = 1.01, p = 0.01). A moderately dilated RV size was also associated with ECMO flow (OR = 2.62, p < 0.001) and ECMO duration (OR = 1.02, p = 0.02). An increasing degree of RV dysfunction was associated with worse outcomes. Our study showed that the increasing duration and flow of VV-ECMO correlated with progressive RV dilatation and dysfunction, which were associated with poor survival.


  • Open Access

    Association between Impella device support and elevated rates of gout flares: a retrospective propensity-matched study

    by Jorge Sinclair De Frías, Shahin Isha, Lorenzo Olivero, Lekhya Raavi, Sai Abhishek Narra, Smit Paghdar, Sadhana Jonna, Parthkumar Satashia, Rachel Hannon, Jessica Blasavage, et al.

    Background: Impella is an advanced ventricular assist device frequently used as a bridge to heart transplantation. The association of Impella with increased rates of gout flares has not been studied. Our primary aim is to determine the rates of gout flares in patients on Impella support. Methodology: A retrospective study was conducted between January 2017 and September 2022 involving all patients who underwent heart transplantation. The cohort was divided into two groups based on Impella support for statistical analysis. In patients receiving Impella support, outcome measures were compared based on the development of gout flares. 1:1 nearest neighbor propensity match, as well as inverse propensity of treatment weighted analyses, were performed to explore the causal relationship between impella use and gout flare in our study population. Results: Our analysis included 213 patients, among which 42 (19.71%) patients were supported by Impella. Impella and non-Impella groups had similar age, race, and BMI, but more males were in the Impella group. Gout and chronic kidney disease were more prevalent in Impella-supported patients, while coronary artery disease was less common. The prevalence of gout flare was significantly higher in Impella patients (30.9% vs. 5.3%). 42 Impella-supported patients were matched with 42 patients from the non-impella group upon performing a 1:1 propensity matching. Impella-supported patients were noted to have a significantly higher risk of gout flare (30.9% vs. 7.1%, SMD = 0.636), despite no significant difference in pre-existing gout history and use of anti-gout medications. Impella use was associated with a significantly increased risk of gout flare in unadjusted (OR 8.07), propensity-matched (OR 5.83), and the inverse propensity of treatment-weighted analysis (OR 4.21). Conclusion: Our study is the first to identify the potential association between Impella support and increased rates of gout flares in hospitalized patients. Future studies are required to confirm this association and further elucidate the biological pathways. It is imperative to consider introducing appropriate measures to prevent and promptly manage gout flares in Impella-supported patients.

  • Letter to the Editor: Improvement in Palliative Care Utilization and Provider Confidence With Respiratory Distress Observation Scale: A Single-Center Experience

    by Mary Kindred, Shahin Isha, Abby Hanson, Parthkumar Satashia, Ashley Thompson, Cathy Mielke, Devang Sanghavi

    Journal of Palliative Medicine